Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.
Arshad U, Pertinez H, Box H, Tatham L, Rajoli RKR, Curley P, Neary M, Sharp J, Liptrott NJ, Valentijn A, David C, Rannard SP, O'Neill PM, Aljayyoussi G, Pennington SH, Ward SA, Hill A, Back DJ, Khoo SH, Bray PG, Biagini GA, Owen A. Arshad U, et al. Clin Pharmacol Ther. 2020 Oct;108(4):775-790. doi: 10.1002/cpt.1909. Epub 2020 Jun 14. Clin Pharmacol Ther. 2020. PMID: 32438446 Free PMC article. Review.
Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis.
Rajoli RK, Pertinez H, Arshad U, Box H, Tatham L, Curley P, Neary M, Sharp J, Liptrott NJ, Valentijn A, David C, Rannard SP, Aljayyoussi G, Pennington SH, Hill A, Boffito M, Ward SA, Khoo SH, Bray PG, O'Neill PM, Hong WD, Biagini G, Owen A. Rajoli RK, et al. medRxiv [Preprint]. 2020 May 6:2020.05.01.20087130. doi: 10.1101/2020.05.01.20087130. medRxiv. 2020. PMID: 32511548 Free PMC article. Updated. Preprint.
Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis.
Rajoli RKR, Pertinez H, Arshad U, Box H, Tatham L, Curley P, Neary M, Sharp J, Liptrott NJ, Valentijn A, David C, Rannard SP, Aljayyoussi G, Pennington SH, Hill A, Boffito M, Ward SA, Khoo SH, Bray PG, O'Neill PM, Hong WD, Biagini GA, Owen A. Rajoli RKR, et al. Br J Clin Pharmacol. 2021 Apr;87(4):2078-2088. doi: 10.1111/bcp.14619. Epub 2020 Dec 1. Br J Clin Pharmacol. 2021. PMID: 33085781 Free PMC article.
Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection.
Hobson JJ , Savage AC , Dwyer AB , Unsworth C , Massam J , Arshad U , Pertinez H , Box H , Tatham L , Rajoli RKR , Neary M , Sharp J , Valentijn A , David C , Curley P , Liptrott NJ , McDonald TO , Owen A , Rannard SP . Hobson JJ , et al. Nanoscale. 2021 Apr 7;13(13):6410-6416. doi: 10.1039/d1nr00309g. Epub 2021 Mar 25. Nanoscale. 2021. PMID: 33885522
Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisation.
Halamoda-Kenzaoui B, Vandebriel RJ, Howarth A, Siccardi M, David CAW, Liptrott NJ, Santin M, Borgos SE, Bremer-Hoffmann S, Caputo F. Halamoda-Kenzaoui B, et al. J Control Release. 2021 Aug 10;336:192-206. doi: 10.1016/j.jconrel.2021.06.016. Epub 2021 Jun 12. J Control Release. 2021. PMID: 34126169 Free PMC article. Review.
53 results